Breaking News, Trials & Filings

STADA, Bio-Thera Win EU Clearance for Simponi Biosimilar

European Commission grants approval for Gotenfia, a golimumab biosimilar to Simponi that was developed by Bio-Thera and will be marketed by STADA.

Author Image

By: Charlie Sternberg

Associate Editor

The European Commission has approved STADA and Bio-Thera Solutions’ Gotenfia, a biosimilar to Johnson & Johnson’s Simponi, clearing the way for its rollout across the European Union and European Economic Area. The authorization covers multiple chronic inflammatory autoimmune conditions and follows a positive recommendation issued in December 2025 by the European Medicines Agency’s Committee for Medicinal Products for Human Use. STADA said launch preparations are underway, with product ava...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters